Associated Papers
Analytical and clinical validation of a novel CE-IVD kit for PIK3CA hotspot mutations in liquid biopsy samples.
Stergiopoulou D et al.
The Journal of Liquid Biopsy, 2026
Hormone Receptor Positive/HER2 Negative Breast Carcinoma: Association of PIK3CA Mutational Status with PD-L1 and Tumor Cell Microenvironment and Their Prognostic Significance.
Lopac D et al.
International Journal of Molecular Sciences, 2025
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression.
Klocker EV et al.
Molecular Oncology, 2025
Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients.
Borkar S et al.
Cancers, 2025
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
Bardia A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.
Terán E et al.
Cancer Medicine, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
Ketcham JM et al.
Journal of Medicinal Chemistry, 2024
Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety.
Tokat ÜM et al.
Therapeutic Advances in Medical Oncology, 2024
PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma.
Choi S et al.
The Journal of Pathology, 2023
Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival.
Sayagués JM et al.
International Journal of Molecular Sciences, 2023
PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients.
Kim JW et al.
Cancer Research and Treatment, 2023
Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations.
Sivakumar S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
[Characteristics of PIK3CA gene mutations in Her2-low breast cancer].
Pavlenko IA et al.
Arkhiv Patologii, 2023
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Howell SJ et al.
The Lancet. Oncology, 2022
Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: A case report and literature review.
Chu Z
Frontiers in Oncology, 2022
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Burstein HJ et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2021
Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors.
Hieggelke L et al.
Cancers, 2021
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
Jhaveri K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).
Santin AD et al.
Gynecologic Oncology Reports, 2020
A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.
Anderson EJ et al.
International Journal of Breast Cancer, 2020
Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer.
Zhang Y et al.
Frontiers in Cell and Developmental Biology, 2020
Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung Cancer.
Qiu Y et al.
Frontiers in Oncology, 2020
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.
Kim JY et al.
International Journal of Cancer, 2019
Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer.
Seo AN et al.
Anticancer Research, 2019
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Dickler MN et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Caumanns JJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer.
Kim JW et al.
Oncotarget, 2017
Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.
García-Saenz JA et al.
Bmc Cancer, 2017
BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK et al.
Plos One, 2016
High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.
Jacot W et al.
Bmc Cancer, 2015
Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P et al.
Plos One, 2015
Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
Schleifman EB et al.
Plos One, 2014